Skip to content
    Mission BioCapital logo

    Mission BioCapital

    Cambridge, Massachusetts, United StatesFounded 2009
    www.missionbiocapital.comLinkedIn
    Biotech & Life SciencesHealthcare

    Mission BioCapital is an early-stage life science venture capital firm that provides capital, shared lab space, and strategic support to biotech entrepreneurs. Formed by the merger of BioInnovation Capital and Mission Bay Capital, it invests in novel therapeutics, diagnostics, and medtech companies.

    55% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $55.0M (across 29 rounds with reported amounts).

    Find people at Mission BioCapital on Goldilocks AI

    Portfolio

    28

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    3

    Team

    Douglas Crawford, PhD

    Douglas Crawford, PhD

    Managing General Partner

    Johannes Fruehauf, MD PhD

    Johannes Fruehauf, MD PhD

    General Partner

    Peter Parker

    Peter Parker

    Managing General Partner

    Steve Tregay, PhD

    Steve Tregay, PhD

    Managing General Partner

    Ulrik B. Nielsen

    Ulrik B. Nielsen

    General Partner

    Cassidy Blundell, PhD

    Cassidy Blundell, PhD

    Partner

    Jennifer Griffin, PhD

    Jennifer Griffin, PhD

    Partner

    Michael Taylor, PhD

    Michael Taylor, PhD

    Operating Partner

    Robert Blazej, PhD

    Robert Blazej, PhD

    Partner

    Zach Collins, PhD

    Zach Collins, PhD

    Partner

    Linda Eng

    Linda Eng

    Director of Operations, Bay Area

    Mark Byrnes

    Mark Byrnes

    Director of Operations, Cambridge

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    33 investments
    CompanyRoundAmountDate
    BBeech BiotechPre-Seed$500KApr 2026
    BBeech BiotechSeed—Apr 2026
    Zag Bio logoZag BioSeries A$80MOct 2025
    Sensorium Therapeutics logoSensorium TherapeuticsSeries A$25MAug 2025
    SiteOne Therapeutics logoSiteOne TherapeuticsSeries C$100MDec 2024
    Alessa Therapeutics logoAlessa TherapeuticsSeed$15MDec 2024
    Nuvig Therapeutics logoNuvig TherapeuticsSeries B$161MDec 2024
    Integrated Biosciences logoIntegrated BiosciencesSeed—Oct 2024
    ImmunOS logoImmunOSUnknown$11MSep 2024
    ImmunOs logoImmunOsSeries C$11MSep 2024
    Progentos Therapeutics logoProgentos TherapeuticsSeries A$65MMay 2024
    VVolnaySeries A$28.4MJan 2024
    QQualis CorporationSeries B$88MMar 2023
    ImmunOS logoImmunOSSeries B$74MJun 2022
    ImmunOs logoImmunOsSeries B$74MJun 2022
    Arkuda Therapeutics logoArkuda TherapeuticsSeries B$64MFeb 2022
    Asher Bio logoAsher BioSeries B$108MSep 2021
    AAsher BiotherapeuticsSeries B$108MSep 2021
    Vedere Bio I logoVedere Bio ISeries A$77MMay 2021
    VVedere BioSeries A$77MMay 2021
    Vaxess Technologies logoVaxess TechnologiesSeries B$25MJan 2021
    TTotientSeed$10MSep 2020
    Symbiome logoSymbiomeSeries A$8MJan 2019
    Symbiome logoSymbiomePre-Seed$15MJan 2017
    QurAlis logoQurAlisSeries B$88M—
    Page 1 of 2

    Top Co-Investors

    Pfizer Ventures6 shared
    Dolby Family Ventures5 shared
    RA Capital Management5 shared
    Samsara BioCapital4 shared
    Sanofi Ventures4 shared
    INKEF Capital4 shared
    Alexandria Venture Investments4 shared
    BioMed Ventures4 shared
    Gimv4 shared
    Atlas Venture3 shared
    Cormorant Asset Management3 shared
    Lightspeed Venture Partners3 shared
    Wellington Management3 shared
    Casdin Capital2 shared
    RD Fund2 shared
    Surveyor Capital2 shared
    EQT Life Sciences2 shared
    Dementia Discovery Fund2 shared
    ALS Investment Fund2 shared
    Mitsui & Co. Global Investment, Inc.2 shared

    Last updated: 8 September 2026